These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 15206502)

  • 1. Effect of moxonidine on lipid subfractions in patients with hypertension.
    Lumb PJ; McMahon Z; Chik G; Wierzbicki AS
    Int J Clin Pract; 2004 May; 58(5):465-8. PubMed ID: 15206502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
    Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
    Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
    Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of moxonidine on plasma lipid profile and on LDL subclass distribution.
    Elisaf MS; Petris C; Bairaktari E; Karabina SA; Tzallas C; Tselepis A; Siamopoulos KC
    J Hum Hypertens; 1999 Nov; 13(11):781-5. PubMed ID: 10578224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
    Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic and antihypertensive effects of nebivolol and atenolol in normometabolic patients with mild-to-moderate hypertension.
    Pesant Y; Marc-Aurèle J; Bielmann P; Alaupovic P; Cartier P; Bichet D; Thibault G; Lupien PJ
    Am J Ther; 1999 May; 6(3):137-47. PubMed ID: 10423656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of abdominal visceral fat, growth hormone, fitness, and insulin on lipids and lipoproteins in older adults.
    Weltman A; Despres JP; Clasey JL; Weltman JY; Wideman L; Kanaley J; Patrie J; Bergeron J; Thorner MO; Bouchard C; Hartman ML
    Metabolism; 2003 Jan; 52(1):73-80. PubMed ID: 12524665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles.
    Guerin M; Lassel TS; Le Goff W; Farnier M; Chapman MJ
    Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):189-97. PubMed ID: 10634817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of moxonidine and amlodipine on serum YKL-40, plasma lipids and insulin sensitivity in insulin-resistant hypertensive patients-a randomized, crossover trial.
    Masajtis-Zagajewska A; Majer J; Nowicki M
    Hypertens Res; 2010 Apr; 33(4):348-53. PubMed ID: 20139920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes.
    Pontrelli L; Parris W; Adeli K; Cheung RC
    Metabolism; 2002 Mar; 51(3):334-42. PubMed ID: 11887170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study.
    Sharma AM; Wagner T; Marsalek P
    J Hum Hypertens; 2004 Sep; 18(9):669-75. PubMed ID: 15269705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
    Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH
    J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipids and lipoproteins during antihypertensive drug therapy. Comparison of doxazosin and atenolol in a randomized, double-blind trial: the Alpha Beta Canada Study.
    Rabkin SW; Huff MW; Newman C; Sim D; Carruthers SG
    Hypertension; 1994 Aug; 24(2):241-8. PubMed ID: 8039850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. I1-imidazoline-receptor agonists in the treatment of hypertension: an appraisal of clinical experience.
    Ollivier JP; Christen MO
    J Cardiovasc Pharmacol; 1994; 24 Suppl 1():S39-48. PubMed ID: 7533226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of mild to moderately elevated triglycerides on low density lipoprotein subfraction concentration and composition in healthy men with low high density lipoprotein cholesterol levels.
    Halle M; Berg A; Baumstark MW; König D; Huonker M; Keul Joseph
    Atherosclerosis; 1999 Mar; 143(1):185-92. PubMed ID: 10208494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperapobetalipoproteinemia with compositional abnormality of LDL and IDL, a characteristic lipoprotein alteration in essential hypertension.
    Ryomoto KI; Suzuki M; Kanazawa A; Hasegawa M; Kimura Y; Yamamura T; Harano Y
    Am J Hypertens; 2000 Jun; 13(6 Pt 1):617-24. PubMed ID: 10912744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoprotein composition in insulin-dependent diabetes mellitus with chronic renal failure: effect of kidney and pancreas transplantation.
    Hughes TA; Gaber AO; Amiri HS; Wang X; Elmer DS; Winsett RP; Hathaway DK; Hughes SM; Ghawji M
    Metabolism; 1994 Mar; 43(3):333-47. PubMed ID: 8139482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of short- and long-term growth hormone replacement on lipoprotein composition and on very-low-density lipoprotein and low-density lipoprotein apolipoprotein B100 kinetics in growth hormone-deficient hypopituitary subjects.
    Kearney T; de Gallegos CN; Proudler A; Parker K; Anayaoku V; Bannister P; Venkatesan S; Johnston DG
    Metabolism; 2003 Jan; 52(1):50-9. PubMed ID: 12524662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.